Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Fineline Cube Jan 26, 2026
Company Drug

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody

Fineline Cube Oct 30, 2025

Shanghai Ark Biopharmaceutical Co., Ltd. (ARK) today announced the official start of a Phase II clinical...

Company

NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ

Fineline Cube Oct 30, 2025

NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now...

Others

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer

Fineline Cube Oct 30, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA:  688180) announced today that its programmed death‑1...

Company Drug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

Fineline Cube Oct 30, 2025

China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...

Policy / Regulatory

National Health Commission Unveils Fourth Drug List for Generic Development

Fineline Cube Oct 30, 2025

The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...

Company

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition

Fineline Cube Oct 30, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third‑quarter earnings call that it no longer...

Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Fineline Cube Oct 29, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...

Company Drug

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment

Fineline Cube Oct 29, 2025

Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...

Company Legal / IP

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China

Fineline Cube Oct 29, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...

Company Deals

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing

Fineline Cube Oct 29, 2025

BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization...

Company Deals

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea

Fineline Cube Oct 29, 2025

IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...

Company Deals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

Fineline Cube Oct 29, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...

Company Deals

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

Fineline Cube Oct 29, 2025

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...

Company Deals

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Fineline Cube Oct 29, 2025

Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...

Company Drug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

Fineline Cube Oct 29, 2025

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...

Company

Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today released its third‑quarter 2025 financial results....

Company

Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA

Fineline Cube Oct 29, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877,  SHA: 688180) today released its third‑quarter 2025 financial results....

Company Deals

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...

Company Deals

Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP

Fineline Cube Oct 29, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary,...

Company Drug

Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer

Fineline Cube Oct 28, 2025

China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...

Posts pagination

1 … 35 36 37 … 614

Recent updates

  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
  • Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
  • MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
  • Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Medical Device

MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.